Clinical Trials Browser

OTHER × Recurrence × polatuzumab vedotin × Clear all

NCT05498220 2025-09-02

Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Phase 2 Active not recruiting

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05940051 2023-07-11

Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Phase 2 Unknown

Recurrence, Lymphoma, Large B-Cell, Diffuse